Name: Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (en Inglés)
Price: 87.89 USD
Availability: InStock
Author: Müller, Rüdiger
ISBN: 9783039430901

portada Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (en Inglés)

Formato

Libro Físico

Editorial

Mdpi AG

Autor

Müller, Rüdiger

Idioma

Inglés

N° páginas

260

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 2.2 cm

Peso

0.76 kg.

ISBN13

9783039430901

Categorías

Cuestiones generales de la medicina

Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (en Inglés)

Müller, Rüdiger (Autor) · Mdpi AG · Tapa Dura

Libro Nuevo

$ 87.89

$ 135.21

Ahorras: $ 47.33

35% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 23 de Julio y el Martes 06 de Agosto.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (en Inglés)"

Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.